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Background Findings Discussion
Reintubation in the post-anesthesia care unit (PACU) is a 
complication that may be related to residual neuromuscular 
blockade. Neostigmine and sugammadex have different 
pharmacokinetics that effect speed and completeness of 
reversal of paralysis. According to Tillquist et al. (2016) 
reintubation following general anesthesia in the PACU is 
associated with a 50% increased risk of mortality. Few studies 
have investigated the incidence rate of PACU reintubation and 
its possible relationship and choice of reversal medication.
• Reintubation in the PACU is rare and there are no significant differences in reintubation rate 
among patients receiving neostigmine or sugammadex. (P = 0.57)
• No reversal = received a non-depolarizing neuromuscular blocker, but did not receive 
reversal agent
• Not requiring reversal = received either a depolarizing neuromuscular blocker or none, and 
subsequently did not require reversal agent
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Methods
• Retrospective Observational Research Study.
• This project was approved by the PSHMC Clinical Innovation 
and Research Council and deemed human subjects exempt  
by the Providence Health Care institutional review board.
• Patient data was extracted from Epic electronic medical 
records and accessed from secured REDCap database.
• Eligibility Criteria: 
• Inclusion – Patients > 18 years of age undergoing 
general anesthesia, intubated at start of procedure and 
extubated by out of OR time between 2013 and 2019. 
• Descriptive analyses examined baseline group 
comparability, incidence of reintubation and reintubation 
risk factors in the study population.
• Additional statistical analyses were conducted: a-priori 
power analysis, univariate, bivariate, and multivariable.
• Time series examined rates of PACU reintubation over time, 
with stratification into low risk and high risk patient groups. 
• Risk factors associated with reintubation were extrapolated 
based upon Bruekmann et al. (2013) score for prediction of 
postoperative respiratory complications (SPORC).
Reintubation in the PACU is rare. Rates of reintubation 
increased in the years 2016 and 2017. Rates in 2019 were 
below levels observed in 2014. Patients were stratified into 
low risk (reintubation risk score 0-2) and high risk (>3) groups. 
Reintubation rates peaked for high risk patients in 2016 and 
peaked for low risk patients in 2017. A reduction of 
reintubation in PACU was not associated with the utilization of 
sugammadex in comparison to neostigmine. 
Due to the lack of current research evidence investigating the 
relationship between reintubation rates and reversal 
medication, this retrospective observational research study 
aims to serve as a foundation for generating hypotheses for 
future randomized control trials that may inform treatment 
decisions in clinical practice. 
Table 1. Patient Demographic & Clinical Characteristics 
(N=84,582)
Variable Value Mean SD
Age Years 57 17




































































*ASA Score: American Society of Anesthesiology Physical Status Classification;
**Patient Risk Score: Age > 70, BMI > 40, ASA > 3, pre-existing respiratory disease,
case duration > 180 minutes, and/or administration of opioids within 30 minutes













Neostigmine Sugammadex No Reversal Not Requiring
Reversal























2014-2016 Pre-Sugammadex / 2016-2019 Post-Sugammadex
Figure 2. Time Series of Reintubation Rates





Table 2. *Independent Risk Factors for PACU Reintubation
OR (95% CI) coeff b P-value
Neostigmine 1.01 (0.61-1.67) 0.01 0.95
Sugammadex 0.92 (0.56-1.52) -0.07 0.75
High Risk Patients 1.67 (1.08-2.56) 0.51 0.01
Non-Elective Procedure 1.96 (1.25-3.09) 0.67 0.003
*Multivariable Binary Logistic Regression Analysis
